L

Lytix Biopharma AS
OSE:LYTIX

Watchlist Manager
Lytix Biopharma AS
OSE:LYTIX
Watchlist
Price: 6.8 NOK -0.29% Market Closed
Market Cap: 337.4m NOK
Have any thoughts about
Lytix Biopharma AS?
Write Note

Lytix Biopharma AS
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Lytix Biopharma AS
Cash & Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
L
Lytix Biopharma AS
OSE:LYTIX
Cash & Cash Equivalents
kr27.4m
CAGR 3-Years
-1%
CAGR 5-Years
-11%
CAGR 10-Years
N/A
Hofseth Biocare ASA
OSE:HBC
Cash & Cash Equivalents
kr23.4m
CAGR 3-Years
-35%
CAGR 5-Years
-27%
CAGR 10-Years
41%
B
Bergenbio ASA
OSE:BGBIO
Cash & Cash Equivalents
kr174.8m
CAGR 3-Years
-30%
CAGR 5-Years
-10%
CAGR 10-Years
N/A
Arcticzymes Technologies ASA
OSE:AZT
Cash & Cash Equivalents
kr170m
CAGR 3-Years
-3%
CAGR 5-Years
50%
CAGR 10-Years
7%
N
Nykode Therapeutics ASA
OSE:NYKD
Cash & Cash Equivalents
$136.5m
CAGR 3-Years
-8%
CAGR 5-Years
29%
CAGR 10-Years
N/A
T
Thor Medical ASA
OSE:TRMED
Cash & Cash Equivalents
kr29.6m
CAGR 3-Years
-60%
CAGR 5-Years
-42%
CAGR 10-Years
-5%
No Stocks Found

Lytix Biopharma AS
Glance View

Market Cap
337.4m NOK
Industry
Biotechnology

Lytix Biopharma AS develops novel drugs for the treatment of resistant bacterial and fungal infections, as well as oncology treatments. The company is headquartered in Oslo, Oslo. The company went IPO on 2021-06-14. The firm's product, LTX-315, is a oncolytic molecule representing a new and superior in situ therapeutic vaccination principle to boost anti-cancer immunity, with the potential to be the ideal combination partner with other types of immunotherapy. LTX-315 targets cancer cells and disintegrates their cell membranes, causing immunogenic cell death and release of a patient’s tumor specific antigens. This mode of action allows cytotoxic T cells to recognize, infiltrate, and attack cancer cells. The firm serves customers domestically.

LYTIX Intrinsic Value
0.9 NOK
Overvaluation 87%
Intrinsic Value
Price
L

See Also

What is Lytix Biopharma AS's Cash & Cash Equivalents?
Cash & Cash Equivalents
27.4m NOK

Based on the financial report for Dec 31, 2023, Lytix Biopharma AS's Cash & Cash Equivalents amounts to 27.4m NOK.

What is Lytix Biopharma AS's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
-11%

Over the last year, the Cash & Cash Equivalents growth was -71%. The average annual Cash & Cash Equivalents growth rates for Lytix Biopharma AS have been -1% over the past three years , -11% over the past five years .

Back to Top